Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis

被引:4
|
作者
Gao, Fenghua [1 ]
Zhang, Tingting [1 ]
Liu, Hengqi [1 ]
Li, Wei [1 ]
Liu, Xianming [1 ]
Qiu, Lihua [1 ]
Li, Lanfang [1 ]
Zhou, Shiyong [1 ]
Qian, Zhengzi [1 ]
Dong, Sitong [2 ]
Zhao, Sai [2 ]
Wang, Xianhuo [1 ]
Zhang, Huilai [1 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Dept Lymphoma, Sino US Ctr Lymphoma & Leukemia Res,Key Lab Canc, Huanhuxi Rd, Tianjin 300060, Peoples R China
[2] Systemat Review Solut Ltd, Ingenu Ctr, Nottingham, England
基金
中国国家自然科学基金;
关键词
Follicular lymphoma; POD24; Risk factors; Meta-analysis; Systematic review; SOLUBLE INTERLEUKIN-2-RECEPTOR LEVEL; METABOLIC TUMOR VOLUME; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PROGRESSION-FREE SURVIVAL; MINIMAL RESIDUAL DISEASE; PROGNOSTIC VALUE; 1ST-LINE TREATMENT; PREDICTS SURVIVAL; DIAGNOSIS; DOXORUBICIN;
D O I
10.1007/s00277-022-04914-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progression of disease within 24 months (POD24) is strongly associated with a poor outcome in patients with follicular lymphoma (FL). Our study aimed to identify the potential risk factors for POD24 in patients with FL. Medline, EMBASE and the Cochrane Library were systematically searched from the earliest record to September 2020. Studies investigating the prognostic factors for POD24 in patients with newly diagnosed grade 1-3a FL were included. Among 10,014 pieces of literature, a total of 90 studies investigating 82 risk factors were included for qualitative analysis. Meta-analyses were performed in 31 studies with 11 factors. Results showed that elevated sIL-2R, beta 2m and LDH, total metabolic tumour volume > 510 cm(3), vitamin D < 20 ng/mL, grade 3a and lymphoma-associated macrophages/high-power field >= 15 were significantly associated with an increased risk of POD24. No significant association was found between POD24 and the ALC/AMC ratio, sex, T effector signature or EZH2 genetic alteration. Additionally, minimal residual disease, Ki-67, PD-1 and TP53 were analysed narratively. Overall, this is the first study that comprehensively analysed the prognostic factors associated with POD24 in FL patients. We have confirmed the significance value of several common prognostic factors as well as others not commonly included in clinical study, helping to construct an integrated and more efficient model.
引用
收藏
页码:2383 / 2392
页数:10
相关论文
共 50 条
  • [41] Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
    Clara Sortais
    Anne Lok
    Benoit Tessoulin
    Thomas Gastinne
    Béatrice Mahé
    Viviane Dubruille
    Nicolas Blin
    Cyrille Touzeau
    Anne Moreau
    Céline Bossard
    Pierre Peterlin
    Alice Garnier
    Thierry Guillaume
    Amandine Le Bourgeois
    Patrice Chevallier
    Philippe Moreau
    Christophe Leux
    Steven Le Gouill
    Annals of Hematology, 2020, 99 : 1595 - 1604
  • [42] Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials
    Vidal, Liat
    Gafter-Gvili, Anat
    Salles, Gilles
    Dreyling, Martin H.
    Ghielmini, Michele
    Schmitz, Shu-Fang Hsu
    Pettengell, Ruth
    Witzens-Harig, Mathias
    Shpilberg, Ofer
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (23): : 1799 - 1806
  • [43] Re: Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized trials
    Tuccori, Marco
    Focosi, Daniele
    Blandizzi, Corrado
    Del Tacca, Mario
    Petrini, Mario
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (18): : 1288 - 1289
  • [44] Re: Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized trials
    Landgren, Ola
    Dunleavy, Kieron
    Wilson, Wyndham H.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (18) : 1287 - 1288
  • [45] Frontline therapy with Bendamustine and rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma
    Freeman, Ciara Louise
    Savage, Kerry J.
    Villa, Diego
    Scott, David W.
    Gerrie, Alina S.
    Ferguson, David J.
    Cafferty, Fergus
    Slack, Graham W.
    Farinha, Pedro
    Skinnider, Brian
    Connors, Joseph M.
    Sehn, Laurie H.
    BLOOD, 2018, 132
  • [46] Prevalence and risk factors of sarcopenia in patients with stroke: a systematic review and meta-analysis
    Xiang He
    Xiping Shen
    Tingting Yang
    Guifen Ma
    Jinhan Nan
    Juanjuan Feng
    Fanghong Yan
    Cuilian Wang
    Lin Han
    Yanan Zhang
    Yuxia Ma
    Neurosurgical Review, 48 (1)
  • [47] Risk factors for mortality in patients undergoing hemodialysis: A systematic review and meta-analysis
    Ma, Lijie
    Zhao, Sumei
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 238 : 151 - 158
  • [48] Risk factors for fear of falling in stroke patients: a systematic review and meta-analysis
    Xie, Qi
    Pei, Juhong
    Gou, Ling
    Zhang, Yabin
    Zhong, Juanping
    Su, Yujie
    Wang, Xinglei
    Ma, Li
    Dou, Xinman
    BMJ OPEN, 2022, 12 (06):
  • [49] Risk factors for suicidality in patients with panic disorder: A systematic review and meta-analysis
    Tietbohl-Santos, Barbara
    Chiamenti, Paula
    Librenza-Garcia, Diego
    Cassidy, Ryan
    Zimerman, Aline
    Manfro, Gisele Gus
    Kapczinski, Flavio
    Passos, Ives Cavalcante
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2019, 105 : 34 - 38
  • [50] Prevalence and Risk Factors of Frailty in Stroke Patients: A Meta-Analysis and Systematic Review
    Y. N. Huang
    F. H. Yan
    X. Y. Wang
    X. L. Chen
    H. Y. Chong
    W. L. Su
    Y. R. Chen
    Lin Han
    Yuxia X. Ma
    The journal of nutrition, health & aging, 2023, 27 : 96 - 102